Using Biomarkers to Manage Therapy in Advanced Colorectal Cancer

Por Messersmith, Wells
Publicado em 2012

Oxaliplatin-Induced Neuropathy in Colorectal Cancer

Por Weickhardt, Andrew, Wells, Keith, Messersmith, Wells
Publicado em 2011

Current Status of Src Inhibitors in Solid Tumor Malignancies

Por Puls, Lauren N., Eadens, Matthew, Messersmith, Wells
Publicado em 2011

Chemotherapy Agents: A Primer for the Interventional Radiologist

Por Mihlon, Frank, Ray, Charles E., Messersmith, Wells
Publicado em 2010

Anti-Ma2 Paraneoplastic Encephalitis in Association with Recurrent Cervical Cancer

Por Ney, Douglas E., Messersmith, Wells, Behbakht, Kian
Publicado em 2014

Therapeutic Approaches to RAS Mutation

Por Scott, Aaron J, Lieu, Chris H, Messersmith, Wells A
Publicado no Cancer J (2016)

KRAS Mutation: Comparison of Testing Methods and Tissue Sampling Techniques in Colon Cancer

Por Franklin, Wilbur A., Haney, Jerry, Sugita, Michio, Bemis, Lynne, Jimeno, Antonio, Messersmith, Wells A.
Publicado em 2010

Direct Ex Vivo Analysis of Activated, Fas-sensitive Autoreactive T Cells in Human Autoimmune Disease

Por Bieganowska, Katarzyna D., Ausubel, Lara J., Modabber, Yalda, Slovik, Elissa, Messersmith, Wells, Hafler, David A.
Publicado em 1997

TNF-blockade in Patients with Advanced Hormone Refractory Prostate Cancer

Por Diaz, Luis A., Messersmith, Wells, Sokoll, Lori, Sinibaldi, Vicki, Moore, Sandy, Carducci, Michael, Eisenberger, Mario
Publicado em 2009

ALDH1B1 Is Crucial for Colon Tumorigenesis by Modulating Wnt/β-Catenin, Notch and PI3K/Akt Signaling Pathways

Por Singh, Surendra, Arcaroli, John, Chen, Ying, Thompson, David C., Messersmith, Wells, Jimeno, Antonio, Vasiliou, Vasilis
Publicado no PLoS One (2015)

Targeting the WNT Signaling Pathway in Cancer Therapeutics

Por Tai, David, Wells, Keith, Arcaroli, John, Vanderbilt, Chad, Aisner, Dara L., Messersmith, Wells A., Lieu, Christopher H.
Publicado no Oncologist (2015)

A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma

Por De Jesus-Acosta, Ana, Laheru, Daniel, Maitra, Anirban, Arcaroli, John, Rudek, Michelle A., Dasari, Arvind, Blatchford, Patrick J., Quackenbush, Kevin, Messersmith, Wells
Publicado no Invest New Drugs (2014)

Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors

Por Jimeno, Antonio, Li, Jing, Messersmith, Wells A., Laheru, Daniel, Rudek, Michelle A., Maniar, Manoj, Hidalgo, Manuel, Baker, Sharyn D., Donehower, Ross C.
Publicado no J Clin Oncol (2008)

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

Por Messersmith, Wells A., Jimeno, Antonio, Ettinger, David, Laheru, Dan, Brahmer, Julie, Lansey, Dina, Khan, Yasmin, Donehower, Ross C., Elsayed, Yusri, Zannikos, Peter, Hidalgo, Manuel
Publicado em 2008

Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer

Por Arcaroli, John J., Touban, Basel M., Tan, Aik Choon, Varella-Garcia, Marileila, Powell, Rebecca W., Eckhardt, S. Gail, Elvin, Paul, Gao, Dexiang, Messersmith, Wells A.
Publicado em 2010

Patient-derived tumour xenografts as models for oncology drug development

Por Tentler, John J., Tan, Aik Choon, Weekes, Colin D., Jimeno, Antonio, Leong, Stephen, Pitts, Todd M., Arcaroli, John J., Messersmith, Wells A., Eckhardt, S. Gail
Publicado em 2012

ALDH1B1 as a Modulator of Pancreatic Adenocarcinoma

Por Singh, Surendra, Arcaroli, John J., Orlicky, David J., Chen, Ying, Messersmith, Wells A., Bagby, Stacey, Purkey, Alicia, Quackenbush, Kevin S., Thompson, David C., Vasiliou, Vasilis
Publicado no Pancreas (2016)

Phase I Study of Continuous Weekly Dosing of Dimethylamino Benzoylphenylurea (BPU) in Patients with Solid Tumours

Por Messersmith, Wells A., Rudek, Michelle A., Baker, Sharyn D., Zhao, Ming, Collins, Connie, Colevas, A. Dimitrios, Donehower, Ross C., Carducci, Michael A., Wolff, Antonio C.
Publicado em 2006

[(18)F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy

Por Ma, Wen Wee, Jacene, Heather, Song, Dongweon, Vilardell, Felip, Messersmith, Wells A., Laheru, Dan, Wahl, Richard, Endres, Chris, Jimeno, Antonio, Pomper, Martin G., Hidalgo, Manuel
Publicado em 2009

Stromal Cell-Derived Factor 1α Mediates Resistance to mTOR-Directed Therapy in Pancreatic Cancer

Por Weekes, Colin D, Song, Dongweon, Arcaroli, John, Wilson, Lora A, Rubio-Viqueira, Belen, Cusatis, George, Garrett-Mayer, Elizabeth, Messersmith, Wells A, Winn, Robert A, Hidalgo, Manuel
Publicado em 2012